Zealand Pharma A/S

Zealand Pharma A/S Earnings Recaps

ZEAL.CO Health Care 1 recap
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 14, 2026

Shares fell 1.3% after the update, a relatively flat reaction. The transcript highlighted pipeline and partnership progress, including positive petrelintide data, but did not provide financial results or updated guidance to assess against expectations.

Key takeaways
  • In the 220-participant ZUPREME-2 trial, petrelintide produced up to 9.2% mean weight loss at week 28; HbA1c fell by up to 0.65 percentage points, versus a 0.23% increase on placebo.
  • GI-related discontinuations in ZUPREME-2 were 1.9% on petrelintide and 1.7% on placebo. In the earlier ZUPREME-1 trial, mean weight loss reached 10.7% at week 42.
  • Zealand said Roche and Zealand launched a global registrational phase III program for petrelintide. Boehringer Ingelheim plans a global regulatory submission for survodutide in obesity in 2027 and is adding phase III trials.
  • Glepaglutide received a positive CHMP opinion in Europe for short bowel syndrome; Zealand also reported positive results for ZP9830, which moved into phase I-B for plaque psoriasis.
  • Management cited more than $2 billion on the balance sheet and outlined investment in its Cambridge research hub and a Generate Biomedicines collaboration.